TARS Tarsus Pharmaceuticals

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences:

  • The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ET
  • The Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET

A live webcast and additional information can be accessed on the events section of the Tarsus . The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.

Media Contact:

Adrienne Kemp

Sr. Director, Corporate Communications

(949) 922-0801

Investor Contact:

David Nakasone

Head of Investor Relations

(949) 620-3223



EN
30/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tarsus Pharmaceuticals

 PRESS RELEASE

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results o...

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter and full-year 2024 financial results and provide a corporate update. Participants may access the webcast . A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim SMID Cap Biotech Conference on Thursday, February 6th, at 6:00 a.m. PT / 9:00 a.m. ETThe Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, at 7:00 a.m. PT / 10:00 a.m. ET A live webcast and additional information can be accessed on the events section of the Tarsus . The replay will b...

 PRESS RELEASE

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Es...

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 Management to host webcast on Tuesday, January 14, 2025, at 8:00 a.m. P.T. / 11:00 a.m. E.T. IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today provided an update on the Company’s key pri...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch